PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapy for the treatment of rare, severe skin diseases with high unmet medical need. Based in Milan, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
Sector
Biopharmaceuticals
Strategies
Telethon
Status
Active
Website
www.pincell.it
Related News
PinCell announces 2 successful in-vivo studies for breakthrough skin disease therapy
PinCell announces the development of a key transgenic mouse model and the appointment of Dr. Antonino Amato as CEO
PinCell Appoints Veteran Biotech and Biopharma Executives to Management Team and Board of Directors
Sofinnova Partners Announces Third Investment from its Italian Fund
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.